EUVIMEDEUVIMED entdecken
Crossref

Whole Blood Viscosity and Thromboembolic Events in Hospitalized Patients with COVID-19: Post hoc Analysis of the ATTACC/ACTIV-4a Trial

Daein Choi, Joshua D Froess, Patrick R Lawler, Mathew D Neal, Ryan Zarychanski, Robert S Rosenson, ATTACC ACTIV-4a Investigators

Thrombosis and Haemostasis · 01.11.2024 · 124 (11) · 1084-1086

DOI: 10.1055/s-0044-1786030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.11.2024. Verfasst von Daein Choi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Metabolism and Lipids Program, Cardiovascular Institute, Marie-Josee and Henry R Kravis Center for Cardiovascular Health, Icahn School of Medicine at…. Die Arbeit nennt 12 Literaturangaben. Gefördert von: National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) CONNECTS program.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Research Letter The coronavirus disease 2019 (COVID-19) posed unprecedented challenges to health care systems worldwide, necessitating comprehensive research efforts to gain a better understanding of its diverse clinical presentations and associated complications. Among the numerous consequences of infection with the severe acute respiratory syndrome coronavirus 2, venous thromboembolism stands out as a critical concern, significantly contributing to both the morbidity and mortality of individuals hospitalized with COVID-19.[ 1 ] [ 2 ] Whole blood viscosity (WBV) serves as a validated measure of the resistance to shear stress encountered during blood flow within the circulatory system. Several studies have directly assessed WBV in COVID-19 patients and consistently reported elevated values when compared with uninfected individuals.[ 3 ] [ 4 ] Alterations in blood viscosity can influence microcirculation, exacerbate inflammation, and potentiate thrombosis, thereby playing a pivotal role in the pathogenesis of COVID-19-associated thromboembolic complications.[ 5 ] In retrospective cohort studies of hospitalized COVID-19 patients, increased high-shear and low-shear blood viscosity were significantly associated with higher in-hospital mortality and poor prognosis.[ 6 ] [ 7 ] Specifically, a 1 centipoise rise in high-shear viscosity was linked to a 36% increased risk of death ( p < 0.001),[ 7 ] and there was a decreased likelihood of being respiratory organ support-free at 21 days, with an odds ratio (OR) of 0.68 ( p < 0.001).[ 6 ] The Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC; NCT04372589) and A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults with COVID-19 (ACTIV-4a; NCT04505774) platforms investigated therapeutic strategies to mitigate the thrombotic risk associated with COVID-19.[ 8 ] [ 9 ] These platforms reported improved survival and clinical outcomes with therapeutic-dose anticoagulation among noncritically ill patients with COVID-19, but not among those with critical illness. In this context, we conducted a post hoc analysis to explore the relationship between WBV and thromboembolic events in hospitalized patients with COVID-19. The study design and primary results of the trial has been previously published.[ 8 ] [ 9 ] The study received approval from the ethics committee and written or oral informed consent was obtained from all participants or their surrogates. Hospitalized patients with COVID-19 were enrolled in the trial. Exclusion criteria included patients with an imminent risk of death, a high risk of bleeding, those receiving dual antiplatelet therapy, individuals with a separate clinical indication for therapeutic-dose anticoagulation, or a history of heparin-induced cytopenia. Detailed exclusion criteria were published in a previous study.[ 8 ] [ 9 ] Estimated blood viscosity was calculated using the Walburn–Schneck model, which has been previously validated in a study involving COVID-19 patients.[ 10 ] [ 11 ] [ 12 ] The primary outcome of interest was composite outcome of 90-day mortality, venous thromboembolism events, and arterial thromboembolism events. Based on the calculated high-shear and low-shear blood viscosity values, participants were categorized into high- and low-blood viscosity groups using the median value. We used chi-square tests for categorical variables and t -tests for continuous variables to assess statistical significance between the high- and low-blood viscosity groups. Multivariable logistic regression was then conducted to determine ORs and their corresponding 95% confidence intervals (CIs) for the primary outcomes. Considered covariates were age, sex and oxygen requirement at presentation. All analyses were performed using SAS 9.4. We considered p -values less than 0.05 as statistically significant, and all p -values were evaluated using two-tailed tests. Baseline characteristics of the study population are presented in [ Table 1 ]. Participants with higher blood viscosity were more likely to be male, of White or Hispanic ethnicity, younger in age, and had fewer comorbidities compared with those with lower blood viscosity. [ Table 2 ] shows the associated of blood viscosity and primary outcome. A total of 149 primary composite outcome events were identified with a total event rate of 15.7%. However, COVID-19 patients with higher high-shear blood viscosity did not exhibit significantly different odds of developing the primary composite outcome (OR: 0.72, 95% CI: 0.51–1.02, p = 0.07). Table 1 Baseline characteristics of the study population Variables High-shear BV lower half High-shear BV upper half p -Value BV range, cP 1.90–2.93 2.94–4.37 Severity status (%) 0.074 Severe 65 (13.7%) 47 (9.9%) Moderate 410 (86.3%) 426 (90.1%) Sex (%)

Autor:innen und Institutionen

  • Metabolism and Lipids Program, Cardiovascular Institute, Marie-Josee and Henry R Kravis Center for Cardiovascular Health, Icahn School of Medicine at Mount Sinai, The Mount Sinai Medical Center, New York, New York, Unit…
  • Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, United States.
  • Division of Cardiology, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada.
  • Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, United States.
  • Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.

Förderung

  • National Institutes of Health (NIH)
  • National Heart, Lung, and Blood Institute (NHLBI) CONNECTS program

Zitieren

APA

Choi, D., Froess, J. D., Lawler, P. R., Neal, M. D., Zarychanski, R., Rosenson, R. S., & ATTACC ACTIV-4a Investigators (2024). Whole Blood Viscosity and Thromboembolic Events in Hospitalized Patients with COVID-19: Post hoc Analysis of the ATTACC/ACTIV-4a Trial. Thrombosis and Haemostasis, 124(11), 1084-1086. https://doi.org/10.1055/s-0044-1786030

Vancouver

Choi D, Froess JD, Lawler PR, Neal MD, Zarychanski R, Rosenson RS, et al. Whole Blood Viscosity and Thromboembolic Events in Hospitalized Patients with COVID-19: Post hoc Analysis of the ATTACC/ACTIV-4a Trial. Thrombosis and Haemostasis. 2024;124(11):1084-1086. doi:10.1055/s-0044-1786030

BibTeX
@article{Choi2024,
  author = {Choi, Daein and Froess, Joshua D and Lawler, Patrick R and Neal, Mathew D and Zarychanski, Ryan and Rosenson, Robert S and ATTACC ACTIV-4a Investigators, ATTACC ACTIV-4a Investigators},
  title = {Whole Blood Viscosity and Thromboembolic Events in Hospitalized Patients with COVID-19: Post hoc Analysis of the ATTACC/ACTIV-4a Trial},
  journal = {Thrombosis and Haemostasis},
  year = {2024},
  volume = {124},
  number = {11},
  pages = {1084--1086},
  doi = {10.1055/s-0044-1786030}
}
Kostenlos starten →